A Phase 4 interventional study of Travoprost 0.004% Ophthalmic Solution (Travatan) and Timolol 0.5% Ophthalmic Solution (Timoptic) in Glaucoma, sponsored by Alcon Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-03-02.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.
Among the 42 studies testing travoprost in Glaucoma, this one is the 15th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2006, is one of 25 in phase 4, and was the 19th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 89 across the 39 interventional studies. Of the 41 that completed or were terminated, 18 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
93 studies in Glaucoma by Alcon: none open now, none under way, none of them phase 3. Of 92 finished, 35 (38%) have results posted.
Among the 93 studies in Glaucoma by Alcon, this one is the 40th largest by enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2006, is one of 37 in phase 4, and was the 40th registered.
Alcon’s Glaucoma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 42 studies testing travoprost in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 93 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.
To evaluate the IOP lowering efficacy and safety fo Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OH or OAG with visual filed abnormality:
Exclusion Criteria:
Travoprost 0.004%
Drug: Travoprost 0.004% Ophthalmic Solution (Travatan)
Timolol 0.5%
Drug: Timolol 0.5% Ophthalmic Solution (Timoptic)
Travoprost at 9 AM + Placebo \& 9 PM
Timolol in each eye, twice daily at 9 AM \& 9 PM
Mean Intraocular Pressure (IOP) at 9 AM
Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.
Time frame: At Week 12 - At the 9 AM time point for the patient's worse eye.
Week 12 - Mean IOP At 4 PM
Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.
Time frame: At the 4 PM time point for the patient's worse eye.
Mean IOP Change From Baseline at 9 AM
Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.
Time frame: Baseline to Week 12 - at 9 AM
Mean IOP Change at 4 PM
Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.
Time frame: Baseline to Week 12 - at 4 PM
111 patients were enrolled in this study at 4 hospitals
| Milestone | Travoprost 0.004% | Timolol 0.5% |
|---|---|---|
| Started | 54 | 57 |
| Completed | 49 | 44 |
| Not completed | 5 | 13 |
Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.
| millimeters mercury (mmHg) | Travoprost 0.004% | Timolol 0.5% |
|---|---|---|
| Mean Intraocular Pressure (IOP) at 9 AM | 16.3 ± 4.27 | 18.1 ± 4.32 |
Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.
| mmHg | Travoprost 0.004% | Timolol 0.5% |
|---|---|---|
| Mean IOP Change From Baseline at 9 AM | -5.1 ± 4.35 | -4.4 ± 4.35 |
Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.
| mmHg | Travoprost 0.004% | Timolol 0.5% |
|---|---|---|
| Week 12 - Mean IOP At 4 PM | 15.7 ± 3.16 | 17.9 ± 4.02 |
Bilateral IOP measurements by Goldmann applanation were performed at 9AM and 4 PM. Two IOP measurements were taken and averaged. If the difference between the first and second reading was greater than 4 mmHg, a third reading was taken and the two nearest readings averaged.
| mmHg | Travoprost 0.004% | Timolol 0.5% |
|---|---|---|
| Mean IOP Change at 4 PM | -5.3 ± 3.69 | -3.7 ± 4.15 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Travoprost 0.004% | — | 0/54 (0%) | 0/54 (0%) |
| Timolol 0.5% | — | 0/57 (0%) | 0/57 (0%) |
| Age, Categorical(Participants) | Travoprost 0.004% | Timolol 0.5% | Total |
|---|---|---|---|
| <=18 years | 2 | 1 | 3 |
| Between 18 and 65 years | 33 | 31 | 64 |
| >=65 years | 19 | 25 | 44 |
| Sex: Female, Male(Participants) | Travoprost 0.004% | Timolol 0.5% | Total |
|---|---|---|---|
| Female | 22 | 26 | 48 |
| Male | 32 | 31 | 63 |
The record gives a start of May 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost